Daniel D. Gretler
Corporate Officer/Principal presso Stanford University
Profilo
Daniel D.
Gretler is a Professor at Stanford University since 2001.
He previously worked as Medical Director at COR Therapeutics, Inc. from 1995 to 2002, as well as in various Vice President roles at Millennium Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He also served as a Faculty Member at The University of Chicago from 1990 to 1992 and as a Principal at Syntex (USA), Inc. from 1992 to 1995.
Gretler received his undergraduate degrees from the University of Southern California and The University of Chicago, and his doctorate from the University of Bern.
Posizioni attive di Daniel D. Gretler
| Società | Posizione | Inizio |
|---|---|---|
| Stanford University | Corporate Officer/Principal | 01/01/2001 |
Precedenti posizioni note di Daniel D. Gretler
| Società | Posizione | Fine |
|---|---|---|
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Chief Tech/Sci/R&D Officer | 01/01/2002 |
Syntex (USA), Inc.
 Syntex (USA), Inc. Pharmaceuticals: MajorHealth Technology Part of Roche Bay Plc, Syntex (USA), Inc. is a private company that manufactures and wholesales pharmaceutical products. The company is based in Palo Alto, CA. | Corporate Officer/Principal | 01/01/1995 |
| The University of Chicago | Corporate Officer/Principal | 01/01/1992 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| PORTOLA PHARMACEUTICALS, INC. | Public Communications Contact | 05/11/2009 |
Formazione di Daniel D. Gretler
| University of Southern California | Undergraduate Degree |
| The University of Chicago | Undergraduate Degree |
| University of Bern | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Syntex (USA), Inc.
Syntex (USA), Inc. Pharmaceuticals: MajorHealth Technology Part of Roche Bay Plc, Syntex (USA), Inc. is a private company that manufactures and wholesales pharmaceutical products. The company is based in Palo Alto, CA. | Health Technology |
- Borsa valori
- Insiders
- Daniel D. Gretler
